Mahek Garg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mahek Garg has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Haesuk Park
Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, USA
2 shared publications - Scott Martin Vouri
Department of Pharmaceutical Outcomes and Policy, College of Pharmacy University of Florida Gainesville Florida USA
2 shared publications - Debbie L. Wilson
Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA
1 shared publication - Jalpa A. Doshi
University of Pennsylvania, Philadelphia, PA
1 shared publication - Justin Puckett
COVIA Health Solutions, Lansdale, PA
1 shared publication - Katherine Elizabeth Ryland
Merck & Co., Inc
1 shared publication
Latest Publications
- 6 September 2024
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 44 (9) , 701-710
Trends in the appropriateness of oral antibiotic prescriptions dispensed in the United States from 2010 to 2018
Background: One of the goals established by the United States National Action Plan to Combat Antibiotic‐Resistant Bacteria is to reduce inappropriate outpatient antibiotic prescriptions by 50% by 2020. Recent data on the achievement of this goal is lacking. The objective of our study was to examine recent trends in the appropriateness of oral antibiotic prescriptions dispensed to a commercially insured population in outpatient settings in the United States to quantify the relative trend in inappropriate antibiotic prescribing from 2010 to 2018.Methods: Our cross‐sectional analysis examined oral antibiotic prescriptions dispensed in outpatient settings using the IBM MarketScan Commercial Data from January 2010 to December 2018. Trends in the annual proportion of antibiotic prescriptions classified as appropriate, potentially appropriate, inappropriate, or without any medical visit during a 7 days look‐back period were estimated using multivariable generalized linear models with Poisson distribution adjusting for beneficiaries' demographic and infectious conditions.Results: Approximately 170 million oral antibiotic prescriptions were dispensed to 86 million beneficiaries during 2010 to 2018. The mean age of the study population was 34.5 (±19.1) years, with 58.4% females and 24.6% children. We observed a 12.9% (95% Confidence Interval [CI] = 12.6%–13.2%; p < 0.01) decline in rates of antibiotic use, from 832 to 727 prescriptions per 1000 beneficiaries, from 2010 to 2018. The proportion of prescriptions classified as appropriate increased by 36.7% (95% CI = 36.4%–36.9%; p < 0.01); potentially appropriate prescriptions increased by 9.3% (95% CI = 9.1%–9.4%; p < 0.01); whereas inappropriate prescriptions and those without a medical visit declined by 11.3% (95% CI = 11.2%–11.4%; p < 0.01) and 14.0% (95% CI = 13.9%–14.2%; p < 0.01), respectively. Similar declining trends were observed in use and proportion of inappropriate prescriptions for broad‐spectrum antibiotics. In 2018, amoxicillin and azithromycin were the most common appropriate and inappropriate prescription fills, respectively.Conclusion: Although antibiotic use and inappropriate prescribing declined steadily from 2010 to 2018 in the United States, this study demonstrates that we have not achieved the national goal of reducing inappropriate antibiotic prescribing by 50%.
- 6 September 2024
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 44 (9) , 701-710
Trends in the appropriateness of oral antibiotic prescriptions dispensed in the United States from 2010 to 2018
Background: One of the goals established by the United States National Action Plan to Combat Antibiotic‐Resistant Bacteria is to reduce inappropriate outpatient antibiotic prescriptions by 50% by 2020. Recent data on the achievement of this goal is lacking. The objective of our study was to examine recent trends in the appropriateness of oral antibiotic prescriptions dispensed to a commercially insured population in outpatient settings in the United States to quantify the relative trend in inappropriate antibiotic prescribing from 2010 to 2018.Methods: Our cross‐sectional analysis examined oral antibiotic prescriptions dispensed in outpatient settings using the IBM MarketScan Commercial Data from January 2010 to December 2018. Trends in the annual proportion of antibiotic prescriptions classified as appropriate, potentially appropriate, inappropriate, or without any medical visit during a 7 days look‐back period were estimated using multivariable generalized linear models with Poisson distribution adjusting for beneficiaries' demographic and infectious conditions.Results: Approximately 170 million oral antibiotic prescriptions were dispensed to 86 million beneficiaries during 2010 to 2018. The mean age of the study population was 34.5 (±19.1) years, with 58.4% females and 24.6% children. We observed a 12.9% (95% Confidence Interval [CI] = 12.6%–13.2%; p < 0.01) decline in rates of antibiotic use, from 832 to 727 prescriptions per 1000 beneficiaries, from 2010 to 2018. The proportion of prescriptions classified as appropriate increased by 36.7% (95% CI = 36.4%–36.9%; p < 0.01); potentially appropriate prescriptions increased by 9.3% (95% CI = 9.1%–9.4%; p < 0.01); whereas inappropriate prescriptions and those without a medical visit declined by 11.3% (95% CI = 11.2%–11.4%; p < 0.01) and 14.0% (95% CI = 13.9%–14.2%; p < 0.01), respectively. Similar declining trends were observed in use and proportion of inappropriate prescriptions for broad‐spectrum antibiotics. In 2018, amoxicillin and azithromycin were the most common appropriate and inappropriate prescription fills, respectively.Conclusion: Although antibiotic use and inappropriate prescribing declined steadily from 2010 to 2018 in the United States, this study demonstrates that we have not achieved the national goal of reducing inappropriate antibiotic prescribing by 50%.
- Open Access
- 5 December 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (6) , 317-328
Real-World Treatment Patterns, Survival, Health Resource use and Costs Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma
Aim: To examine real-world treatment patterns, survival, healthcare resource use and costs in elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL). Methods: 11,880 Medicare pat... Plain language summary – Older patients with DLBCL need more effective treatments Diffuse large B-cell lymphoma (DLBCL) is the most common form of Non-Hodgkin lymphoma, and it becomes more common w... Tweetable abstract A real-world analysis of nearly 12,000 elderly patients with DLBCL observed high rates of hospitalization and hospice use, poor overall survival in later lines of therapy and sub...
- 5 December 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (6) , 317-328
Open AccessReal-World Treatment Patterns, Survival, Health Resource use and Costs Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma
Aim: To examine real-world treatment patterns, survival, healthcare resource use and costs in elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL). Methods: 11,880 Medicare pat... Plain language summary – Older patients with DLBCL need more effective treatments Diffuse large B-cell lymphoma (DLBCL) is the most common form of Non-Hodgkin lymphoma, and it becomes more common w... Tweetable abstract A real-world analysis of nearly 12,000 elderly patients with DLBCL observed high rates of hospitalization and hospice use, poor overall survival in later lines of therapy and sub...
- 11 July 2023
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 43 (9) , 883-893
Oral fluoroquinolones and risk of aortic aneurysm or dissection: A nationwide population‐based propensity score‐matched cohort study
Study Objective: To investigate risk of aortic aneurysm or dissection in patients using oral fluoroquinolones compared to those using macrolides in real‐world clinical practice among a large US general population.Design: Retrospective cohort study design.Data Source: MarketScan commercial and Medicare supplemental databases.Patients: Adults patients with at least one prescription fill for fluoroquinolone or macrolide antibiotics.Intervention: Fluoroquinolone or macrolide antibiotics.Measurements and Main Results: The primary outcome was estimated incidence of aortic aneurysm or dissection associated with the use of fluoroquinolones compared with macrolides during a 60‐day follow‐up period in a 1:1 propensity score‐matched cohort. We identified 3,174,620 patients (1,587,310 in each group) after 1:1 propensity score matching. Crude incidence of aortic aneurysm or dissection was 1.9 cases per 1000 person‐years among fluoroquinolone users and 1.2 cases per 1000 person‐years among macrolide users. In multivariable Cox regression, compared with macrolides, the use of fluoroquinolones was associated with an increased risk of aortic aneurysm or dissection (aHR: 1.34; 95% CI: 1.17–1.54). The association was primarily driven by a high incidence of aortic aneurysm cases (95.8%). Results of sensitivity (e.g., fluoroquinolone exposure ranging from 7 to 14 days (aHR: 1.47; 95% CI: 1.26–1.71)) and subgroup analyses (e.g., ciprofloxacin (aHR: 1.26; 95% CI: 1.07–1.49) and levofloxacin (aHR: 1.44; 95% CI: 1.19–1.52)) remained consistent with main findings.Conclusions: Fluoroquinolone use was associated with a 34% increased risk of aortic aneurysm or dissection compared with macrolide use among a general US population.
- 11 July 2023
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 43 (9) , 883-893
Oral fluoroquinolones and risk of aortic aneurysm or dissection: A nationwide population‐based propensity score‐matched cohort study
Study Objective: To investigate risk of aortic aneurysm or dissection in patients using oral fluoroquinolones compared to those using macrolides in real‐world clinical practice among a large US general population.Design: Retrospective cohort study design.Data Source: MarketScan commercial and Medicare supplemental databases.Patients: Adults patients with at least one prescription fill for fluoroquinolone or macrolide antibiotics.Intervention: Fluoroquinolone or macrolide antibiotics.Measurements and Main Results: The primary outcome was estimated incidence of aortic aneurysm or dissection associated with the use of fluoroquinolones compared with macrolides during a 60‐day follow‐up period in a 1:1 propensity score‐matched cohort. We identified 3,174,620 patients (1,587,310 in each group) after 1:1 propensity score matching. Crude incidence of aortic aneurysm or dissection was 1.9 cases per 1000 person‐years among fluoroquinolone users and 1.2 cases per 1000 person‐years among macrolide users. In multivariable Cox regression, compared with macrolides, the use of fluoroquinolones was associated with an increased risk of aortic aneurysm or dissection (aHR: 1.34; 95% CI: 1.17–1.54). The association was primarily driven by a high incidence of aortic aneurysm cases (95.8%). Results of sensitivity (e.g., fluoroquinolone exposure ranging from 7 to 14 days (aHR: 1.47; 95% CI: 1.26–1.71)) and subgroup analyses (e.g., ciprofloxacin (aHR: 1.26; 95% CI: 1.07–1.49) and levofloxacin (aHR: 1.44; 95% CI: 1.19–1.52)) remained consistent with main findings.Conclusions: Fluoroquinolone use was associated with a 34% increased risk of aortic aneurysm or dissection compared with macrolide use among a general US population.